U.S. Department of Health and Human Services: Expanding Medication Assisted Treatment for Opioid Use DisordersDeadline: June 20, 2017
The purpose of this funding announcement is to solicit applications proposing to test approaches for expanding Medication Assisted Treatment (MAT) for opioid use disorder (OUD) in the general health care sector or linking individuals with OUDs who receive naloxone for the reversal of overdose to MAT in the context of states’ plans for use of the funds authorized under the 21st Century Cures Act.
Research topics may include but are not limited to the following:
- OUD medications provided in emergency departments, pharmacies, inpatient units, and other health care settings.
- Telehealth approaches for providing OUD medications in the general health care sector.
- Models of care in the general health sector that provide a choice of OUD medications to patients.
- Continuity of care models for those receiving medications for OUD. Models of care and delivery designed to expand the provision of OUD medications in primary care including, but not limited to the following: the Massachusetts Nurse Care Manager Model; the Hub and Spoke Model; the Echo Model; other models described in the recent report, Chou R, Korthuis PT, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, McCarty D. Medication-Assisted Treatment Models of Care for Opioid Use Disorder in Primary Care Settings.
- Models of naloxone delivery that offer the opportunity for linkage to MAT after receipt of naloxone for overdose.
- Interim methadone.
- Interim buprenorphine.
Proposed projects must meet the following criteria:
- Projects must leverage an opportunity made available by funding that states receive under SAMHSA TI-17-04.
- Project teams must include relevant single state agency staff as key personnel (or the equivalent).
- Projects must be designed to generate causal inferences on the effects of approaches to expanding MAT using FDA-approved OUD medications in the general healthcare sector or linking those treated with naloxone to MAT on the following outcomes: drug use and/or overdose deaths; length of time on medication, dropout, time to relapse; and at least one other physical or mental health or health-related outcome. Designs may include randomized controlled explanatory trials, randomized controlled pragmatic trials, or other types of controlled designs employing statistical approaches that mitigate bias and support causal inferences. Hybrid effectiveness-implementation designs may also be appropriate, as long as the outcomes studied in the projects are those listed above. Projects may incorporate randomization approaches appropriate to the research question, such as by cluster or timing of implementation. If another method is used to generate the comparison group, perhaps by staged assignment or staged implementation of the approach, it should provide comparable rigor. Randomization may occur at the patient, provider, clinic, or community level, as is appropriate to the research question.
- PDs/PIs must plan to use some of the funds awarded by this FOA to attend an annual meeting of investigators funded under the FOA and engage in other activities, such as periodic conference calls, designed to facilitate appropriate standardization of measures, collaboration and other mechanisms for maximizing the scientific yield from this FOA.
Amount: $2,000,000 is available to fund 3-4 awards.
Eligibility: Public/State controlled institutions of higher education; private institutions of higher education; nonprofit organizations; for-profit organizations including small businesses; governments; independent school districts; public housing authorities/Indian housing authorities; Native American tribal organizations; faith-based or community-based organizations; and regional organizations.